Johns Hopkins’ accelerator for impact-focused entrepreneurs opened up applications for its next cohort.
The JHU Social Innovation Lab will accept up to 10 companies for the next cohort, which begins in the fall. The program is open to entrepreneurs who are Greater Baltimore residents, as well as the Johns Hopkins community.
Montgomery County, particularly Gaithersburg, has become a central hub for vaccine research and development, and to a lesser extent for vaccine manufacturing.
The County is a key vaccine development center “not only for the country, but the world,” said Brad Fackler, senior director for life sciences at the c.
Netherlands-based biotechnology firm MIMETAS has partnered with Roche to develop a new organ-on-a-chip system to support intestinal permeability assessment.
The new system is designed to enable evaluation in perfused three-dimensional (3D) gut tubules in high throughput under exposure to pharmacological compounds. As part of their research, the firms are reported to have grown more than 350 gut tubules under flow to form leak-tight structures.
Altimmune, a drug company based in Gaithersburg, has agreements with investors to raise about $14.7 million, excluding fees and expenses, in a second round of financing. The company plans to sell 15,565 shares of convertible preferred stock and warrants to new and existing investors in a round that the company expects to close around Aug. 21.
September 18, 2017 | 12:00 PM – 2:00 PM – Maryland Department of Commerce World Trade Center Baltimore 401 East Pratt Street, 17th floor
The Maryland Department of Commerce invites you to learn about the new Maryland Defense Diversification Assistance Program that is designed to assist Maryland companies with dependence on US Department of Defense contracts to expand into international markets. The presentation will highlight Australia (particularly the State of Victoria) as a destination for exporting and partnerships.
Muhammad Najee-Ullah has long been interested in technology, and he recognized the potential for art, tech and design to engage youth in Baltimore.
With Pop-Up Robotic Gaming Grounds (PURGG), Najee-Ullah introduces youth to STEAM. At after-school programs and events, PURGG lets students compete with teams of robots to gather items on a field. It’s also about learning what goes into designing and building the robots through educational “Design/Build/Compete” workshops that introduce coding, 3D printing, game design and plenty of other concepts.
9 November 2017 – Munich
Future X Healthcare offers a unique platform to connect key innovation drivers in healthcare for an open and inspiring exchange of ideas, insights and solutions. The one-day event fosters new networks between the worlds of science, industry, VCs, accelerators, start-ups and politics.
The mission for 2017: to shape the future of healthcare by making big data meaningful – from science to patient care. The increasing availability of healthcare data – from genomic profiling, advanced imaging, digital biomarkers to electronic health records and mobile health – creates the foundation and framework for a more targeted, personalized healthcare. Together, we can change the way we do research, prevent and diagnose diseases, and treat patients.
Experience a day full of inspiration at Alte Bayerische Staatsbank in Munich with top speakers, start-up pitches, a networking innovation fair and two brand-new awards.
I’m thrilled to let you know that our gut-on-a-chip work has been published this week in Nature Communications. 350 mini-guts on-a-chip, 20,000 data points, the largest organ-on-a-chip dataset ever published! The paper features the all new 3-lane OrganoPlate®, supporting barrier integrity and transport assays in even more complex tissue models.
Our colleague Elena Naumovska is a major contributor to this work. She joined us last year from the arctic circle to work on gut-on-a-chip models in a collaboration with Galapagos and Sheffield University.
And finally, we’re looking forward to see you at no less than 6 conferences in the coming 6 weeks, starting next week at the WC10 Congress 2017 in Seattle.
With kind regards, Jos Joore Managing Director, MIMETAS
GlaxoSmithKline opened its new $56.6 million vaccines plant in Montrose, Scotland, that will manufacture sterile aluminum salts and includes a microbiology lab. But the small addition comes as a much bigger project has been canceled.
Creatv MicroTech, a biotechnology company developing noninvasive diagnostics for cancer, has received a $250,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health/National Cancer Institute (NIH/NCI) to test the company’s CellSieveTM system for determination of residual disease in lung cancer patients after chemoradiation therapy, and for early detection of lung cancer recurrence. Creatv MicroTech’s discovery of a very large cell, the cancer associated macrophagelike cell (CAML), in patient blood has enabled more informative and reliable blood based cancer diagnostics. The presence of the CAML biomarker indicates the presence of cancer. Creatv developed CellSieveTM technology to capture and analyze CAMLs. In collaboration with The University of Texas MD Anderson Cancer Center in Houston, Creatv will assess the use of CAMLs in lung cancer patients to determine residual disease following treatment. Lung cancer is the leading cause of cancer death, with an estimated 158,040 deaths (86,380 men and 71,660 women) from this disease in 2015. Ideally, treatment should be continued as long as necessary and stopped only after the cancer has been eradicated. The problem is that standard imaging techniques, CT and MRI, cannot detect small residual cancers, and thus treatment regimens may be insufficient for a patient’s individual need. The goal of Creatv’s study is to determine the point at which chemoradiation should be stopped, reducing the likelihood of recurrence. “We are honored to be recognized for the progress we have made in developing precision blood-based cancer diagnostics,” said Cha-Mei Tang PhD, President and CEO of Creatv MicroTech. “Our collaboration with the world renowned MD Anderson Cancer Center and support from the NIH will further demonstrate the value and utility of the CellSieveTM system and CAMLs in the battle against cancer and will ultimately save lives.”
